RMD Sciences
RMD Sciences is a preclinical-stage biotechnology company with a proprietary carbohydrate-based drug identification platform.
​
Our focus is to leverage our platform to identify and synthesize new drug candidates in areas of significant unmet needs.
We have pre-clinical development candidates for Cancer and Alzheimer’s Disease. The guiding company strategy is to develop candidates and sublicense them to pharmaceutical and Venture Capital companies for IND/NDA submission and commercialization.
​
Research
Our Platform
​
To date, we have identified two drug candidates from the platform: both are orally administered, chemically modified carbohydrate derivatives to treat cancers, Alzheimer’s Disease and possibly other neurodegenerative diseases.
We believe the platform will continue to identify unique and novel carbohydrate derivatives which may result in new mechanisms of action, provide manageable benefit/risk profiles, have significant distribution profiles in the human body such as the central nervous system and treat brain tumors, neurodegenerative and neurologic diseases.
​
Cancer
RMD-102
We have successfully isolated and synthesized a small carbohydrate derivative, RMD-102, which we believe represents a new chemical class of anticancer agents.
It has been shown to:
-
induce rapid and potent cancer cell specific apoptosis (colon, breast, melanoma) in in-vitro studies
-
act against both p53 positive and negative cancer cells
-
have a median effective dose (ED50) six times less than the maximum tolerated dose (MTD)
-
no activity against normal intestinal cell replication suggesting a limited toxicity profile
-
be orally active
-
have an established mechanism of action
-
Initial pharmacokinetic studies
Intellectual Property:
The intellectual property around RMD-102 is wholly owned by RMD Sciences Inc.
Alzheimer’s Disease
RMD-101aq
RMD-101aq is a proprietary starch solution consisting of a mixture of several sugar derivatives of differing lengths.
It has been shown to:
-
improve hippocampal-dependent spatial memory in a standard Alzheimer’s Disease (AD) mouse model as assessed by two independent, validated and commonly used behavioral tests: the Barnes Maze Test and the Object Memory Location Test
-
alter the gastrointestinal (GI) microbiome
​
Our Team
Co-founder and CEO
Aki Taira, Executive MBA
Mr. Taira has more than 19 years of experience in corporate management, including finance, in Japan and the United States. In Japan, starting in 2000, he served as COO and CFO of a corporate venture where in six years he contributed to growing the organization from 25 to 500 employees and sales from $0.6 million to $30 million.  Subsequently, he started his own company, Enspirea LLC, in 2010 in the US offering consulting and system development service for US manufacturers, such as automated engineering processes to Ford Motor Company. In 2016 he joined with Dr. Shimomura to found RMD Sciences Inc.
